Investigational drug · Phase 2
AB-729
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Hepatitis b.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "AB-729"
First trial start
2021
Oct 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AB-729", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis b
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "AB-729" as an intervention, largest first.
Assembly BiosciencesIndustry
NCT04820686 · 65 participants · Start May 7, 2021 · Primary completion Mar 30, 2023
Drug: VBR; AB-729 and 1 more · For: Chronic Hepatitis B
Sites: Darlinghurst, Australia; Kogarah, Australia; Liverpool, Australia · 20 sites in all
Arbutus Biopharma CorporationIndustry
NCT04980482 · 43 participants · Start Oct 29, 2021 · Primary completion Mar 13, 2025
Drug: AB-729; Peg-IFNα-2a · For: Chronic Hepatitis b
Sites: Chandler, Arizona; Tucson, Arizona; San Diego, California · 17 sites in all
Antios Therapeutics, IncIndustry
NCT04847440 · 40 participants · Start Mar 30, 2021 · Primary completion Sep 1, 2022
Drug: ATI-2173; Viread and 1 more · For: Hepatitis B, Chronic; Hepatitis D
Sites: Chisinau, Moldova; Kyiv, Ukraine
University of Maryland, BaltimoreAcademic, hospital or other
NCT06154278 · 10 participants (planned) · Start Jul 25, 2024 · Primary completion Dec 1, 2026
Drug: Imdusiran (AB-729) · For: Chronic Hepatitis B
Sites: Baltimore, Maryland
Arbutus Biopharma CorporationIndustry
NCT06245291 · 0 participants · Start May 1, 2024 · Primary completion Aug 1, 2024
Drug: Imdusiran; Durvalumab · For: Hepatitis B, Chronic
Sites: Tbilisi, Georgia; Hong Kong, Hong Kong; Gdansk, Poland · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic.
Thi EP, Ye X, Snead NM, et al. · ACS Infect Dis 2024
- Measuring hepatitis B pgRNA stability using an updated automated HBV pgRNA assay with increased sensitivity.
Anderson M, Stec M, Thi EP, et al. · Hepatol Commun 2023
- Hepatitis B Gene Therapy Coming to Age.
Soriano V · AIDS Rev 2018
Also in development for Chronic Hepatitis b
- GST-HG141Phase 33 trials
Fujian Akeylink Biotechnology Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TQA3605Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- TVAX-008Phase 24 trials
Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.